What Ultralan Treats: Main Uses and Benefits

Ultralan (Fluocortolone) is a potent topical medication applied across domains where additional symptomatic support is needed to address conditions presenting with significant localized discomfort and inflammatory changes. The active components are commonly used to help manage severe dermatoses and anorectal disorders.

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as flare-ups of various types of eczema (e.g., contact, seborrheic, nummular dermatitis), short-term management of certain psoriasis patches, haemorrhoids, and symptoms associated with anal fissures. It is commonly used when symptoms intensify and supportive relief is needed, particularly for managing intense itching, burning, swelling, and localized pain.

The use of this medication assists with maintaining functional stability during periods of heightened symptoms. It is applied when symptoms create noticeable physiological strain, helping to ease the overall symptom burden.

---

“The treatment supports the patient during difficult episodes by easing distress and is applied across therapeutic domains involving heightened symptomatic responses.”

---

Quick Facts: Relief for Acute Inflammation

Domain	Conditions Handled	Symptom Relief Focus
Dermatology	Eczema, Dermatitis, Psoriasis	Intense Itching, Redness, Swelling
Proctology	Haemorrhoids, Anal Fissure symptoms	Local Pain, Burning, Irritation

Regulatory References

1. Ultraproct - Medsafe

Who can and cannot use Ultralan?

The eligibility to use Ultralan (Fluocortolone) is strictly governed by regulatory labeling, which outlines specific contraindications and use restrictions.

---

Absolute Contraindications

Ultralan is contraindicated and must not be used in patients with a known hypersensitivity to Fluocortolone or any other ingredient in the preparation. It is also strictly prohibited if the patient has an active, localized viral infection, such as herpes, shingles, or chicken-pox, at the intended site of application. Use is further prohibited in the presence of untreated primary infections of bacterial, fungal, tuberculous, or syphilitic origin.

---

Conditional and Restricted Use

For all populations, use must be short-term and should generally not exceed one week to minimize risk. Long-term continuous therapy should be avoided in all patient groups, particularly infants and children, due to increased systemic absorption risk. Patients with a co-existing local bacterial or fungal infection are only eligible if the infection is treated with concurrent specific anti-infective therapy. Use during pregnancy and lactation is restricted; it is generally not recommended during the first trimester and must be under a doctor's prescription due to documented risks.

Interactions with other medicines and products

Ultralan (Fluocortolone) is a potent topical glucocorticoid whose official interaction profile is defined by the pharmacokinetic risk associated with systemic absorption. Although systemic levels are typically low with topical use, the potential for drug-drug interactions must be considered, consistent with regulatory guidelines for potent corticosteroids.

Pharmacokinetic Interaction with CYP3A4 Inhibitors

The primary documented interaction concerns substances that interfere with the metabolic clearance of Fluocortolone. Fluocortolone is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with potent CYP3A4 inhibitors reduces the metabolic clearance of systemically absorbed Fluocortolone, resulting in increased plasma concentrations. This interaction is classified by regulatory authorities as clinically significant.

Classification	Interacting Substance Categories
Exposure-Modifying Agents	Potent inhibitors of CYP3A4, such as Ketoconazole
Avoided Combinations	Cobicistat-containing products

Co-treatment with potent inhibitors of CYP3A4 is expected to increase the risk of systemic corticosteroid side-effects and must be avoided unless the therapeutic benefit is determined to outweigh the exposure risk. If co-administration is unavoidable, regulatory documents stipulate that the patient must be monitored for signs of systemic corticosteroid effects. No timing-based interaction rules or food/supplement interactions are explicitly documented in regulatory labeling.

Molecular Control of Inflammatory Gene Expression

The mechanism begins as Fluocortolone acts as a high-affinity agonist for the Intracellular Glucocorticoid Receptor (GR). This activation leads to the receptor-drug complex translocating to the cell nucleus, where it achieves two critical effects: transrepression (turning off pro-inflammatory genes regulated by NF-kappaB and AP-1) and transactivation (turning on anti-inflammatory genes, like Annexin-1). This fundamental genetic switch results in the broad-spectrum modulation of key inflammatory pathways.

---

Blocking the Synthesis of Key Inflammatory Mediators

The genetic shift causes the cell to produce the protein Annexin-1, which directly and indirectly inhibits the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the drug stops the upstream release of arachidonic acid, thereby simultaneously preventing the production of both Prostaglandins and Leukotrienes. This dual blockade of major inflammatory signaling cascades contributes to the attenuation of vascular permeability and the limitation of nociceptive mediator synthesis.

---

Dual Ester Design for Time-Action

The active ingredient is formulated using two different esters—the Pivalate and the Hexanoate. This combination is not a chemical synergy but a time-release strategy: the Pivalate provides a rapid supply of the active compound for a quick onset of GR activation, while the Hexanoate provides a sustained supply for a protracted duration of effect. This dual delivery mechanism supports sustained engagement of the Glucocorticoid Receptor pathway over time.

Instructions for Using Ultralan

Ultralan is typically administered topically as a cream or ointment. Instructions define the required dosage, application method, and duration of use. The medication is to be used strictly as prescribed by a healthcare professional.

---

Dosing and Application Schedule

Age Group	Initial Application Frequency	As Condition Improves
Adults and Children from 1 year	Once or twice daily	Reduce to once daily
Infants 3 months and over	Once daily	Continues once daily

For faster relief on the first day, the ointment or cream may be applied more frequently, up to three or four times under specific clinical guidance.

Procedural Steps

1. Preparation: Wash your hands thoroughly with soap and water before and after application to prevent contamination and limit unintended transfer. The affected area should be cleaned before the product is applied.
2. Application: Apply only a small, thin layer of the cream or ointment directly to the affected skin area and gently rub it in until it disappears.
3. Special Conditions: If applying the ointment to the anal region, a small amount (about the size of a pea) can be smeared around the anus and in the anal ring. For application inside the rectum, the provided nozzle is attached and carefully inserted.

---

Duration of Use

Treatment must be limited to the shortest duration necessary. Guidelines generally advise that the continuous duration of treatment should not exceed three to four weeks. If using in infants or children, the duration should be determined carefully by the physician and is often limited to one to two weeks. If a dose is missed, apply it as soon as you remember, but skip the missed dose if it is almost time for the next scheduled application, and continue with the regular dosing schedule.

Research evidence / Overview of studies

This section outlines the research that has explored the drug's investigative goals and its outcomes in study participants with condition X.

Preclinical Findings and Focus of Investigation

Early studies suggested that the active compound, an anti-inflammatory substance, was associated with a change in the primary inflammatory markers in preclinical models. This research focused on a specific molecular pathway.

This finding was used to hypothesize the compound's potential to investigate symptoms by targeting the core biological issue. Subsequent in vivo studies further examined the compound’s effects on tissue samples, reporting data associated with cellular stress markers.

Phase 1 and 2 Trials: Initial Investigation and Tolerability

Research has evaluated the drug’s long-term use in condition X. Phase 1 trials focused primarily on safety and defined parameters for investigation. Phase 2 trials explored preliminary efficacy in a small cohort of patients.

Key Phase 2 findings:

• Researchers examined whether the drug was associated with a favorable tolerability profile compared to placebo.
• Studies suggested that participants receiving the active compound was associated with a change in Symptom Score-A related to dosage.

Phase 3 Trials: Symptom Outcomes

Phase 3 trials involved a larger, randomized, double-blind, placebo-controlled design.

Primary Study Outcomes

In Phase 3, the drug was evaluated in comparison to a current standard of care, with researchers examining whether the compound was associated with a sustained change of symptoms. The primary outcome measure was the Patient-Reported Outcome (PRO) score at Week 12.

The key study reported that researchers reported a measured change in quality of life (QoL) and a difference in pain scores. Secondary analyses investigated whether this difference was consistent across various patient subgroups, such as disease duration and age.

Quality of Life and Functional Assessment

Further analyses explored the impact of the compound on physical function, using validated functional assessment tools. This research has been used to assess the treatment's potential role for further research. Subgroup analyses also examined the compound's outcomes in study participants with severe versus moderate condition X.

Summary of Research

The combined data was used to characterize the investigated outcomes for study participants. Research has included people of various ages with condition X. Further research is exploring the compound in more detail and evaluating its performance in different treatment settings.

Common questions about Ultralan (FAQ)

---

Q: What should be done if a potential drug interaction is suspected while using Ultralan?

Official regulatory documents warn that certain potent inhibitors of the CYP3A4 enzyme can potentially increase the body's exposure to the medication. Because of this, co-administration of such drugs is generally advised against in official documents unless the patient is being monitored. If there is a need to use specific interacting medicines, regulatory documents describe the necessity for the patient to be monitored by a healthcare professional for signs of systemic corticosteroid effects.

---

Q: What types of diseases is Ultralan primarily authorized to treat?

Official documents describe Ultralan for use in conditions that may benefit from its anti-inflammatory properties, where it is associated with a reduction of symptoms like severe redness, swelling, and intense irritation. Official documentation notes its authorized use for inflammatory skin disorders such as eczema and dermatitis. It is also described for use in certain conditions affecting the anorectal area, including haemorrhoids and proctitis.

---

Q: Is it described anywhere that stopping Ultralan suddenly causes an issue?

Long-term or high-dose use of this class of medicine can suppress the body's natural production of steroid hormones, known as HPA axis suppression. Because of this risk, official regulatory documents for this drug class often describe the practice of gradually reducing the application (tapering) under the supervision of a healthcare professional. This process is intended to allow the body's natural hormone processes to recover.

---

Q: What does 'contraindication' mean in relation to Ultralan?

In official regulatory language, a contraindication defines conditions or circumstances under which the medicine is prohibited from use. These are situations where the risk of using the product significantly outweighs any potential benefit. For Ultralan, examples include a known hypersensitivity to the ingredients or the presence of an active viral or bacterial infection at the application site.

---

Q: Does the effectiveness of Ultralan depend on the underlying skin condition?

The official classification confirms the medicine's role in moderating inflammatory responses for localized skin issues. Regulatory documentation lists specific inflammatory conditions, such as dermatitis and eczema, as authorized uses. This indicates that the medicine's utility is tied to the underlying nature of the disorder and its responsiveness to this specific anti-inflammatory action.

---

Q: What is the most frequently reported side effect in clinical studies of Ultralan?

According to official safety data, the most common or 'frequent' local reactions reported include sensations of burning, stinging, and irritation at the site of application. While these effects are noted in regulatory documents, a single side effect that is statistically ranked as the most frequently reported one is not specified in the readily available information.

---

Q: Is there a limit on the total body surface area that Ultralan can be applied to?

Official regulatory warnings caution against applying the product to large surface areas of the body or using occlusive dressings. This restriction is based on the increased risk of the medicine being absorbed into the body's circulation (systemic absorption). While the risk is clearly identified, official documentation does not typically specify a precise percentage limit for the total body surface area.

---

Q: What does the term 'absorption' mean regarding Ultralan and the skin?

In official context, absorption refers to the medicine passing through the skin and entering the body’s general circulation, which is called a systemic effect. Regulatory warnings exist because significant systemic absorption can lead to a serious issue called Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This means the body's natural steroid production may be reduced.

---

Q: Does Ultralan affect the results of any common medical tests?

The medicine is classified as a potent corticosteroid, and this drug class is associated with the potential for metabolic changes if significant amounts are absorbed systemically. Specifically, official safety documents note that systemic effects can manifest as hyperglycemia, or elevated blood sugar. If systemic absorption occurs, this could potentially impact the results of certain blood tests, such as blood glucose readings.

---

Q: Can Ultralan be used near or on the eyes?

Official patient information notes the instruction to carefully avoid getting the product near the eyes. Furthermore, the medication is generally restricted from use on the face. This restriction is noted in regulatory documents to minimize the risk of adverse effects.

---

Q: What is the difference between Ultralan cream and Ultralan ointment, if both exist?

Official patient information indicates that the formulation choice is often guided by the skin condition being treated. The cream form is typically used for affected areas that are described as moist or weeping. Conversely, the ointment form is generally recommended for skin that is very dry.

---

Q: Does Ultralan have a known risk classification regarding impaired driving or operating machinery?

Regulatory documents, such as the Summary of Product Characteristics (SmPC) for this medicine, state that no effects are known regarding the ability to drive or use machinery. This statement is included to provide factual clarity on potential impairment.

---

Q: Is Ultralan available over-the-counter or is a prescription always required?

The medication is classified as a potent corticosteroid (Group III), which typically requires medical oversight. Official instructions emphasize that the product is to be used strictly as prescribed by a healthcare professional. This indicates that the medicine is not available over-the-counter and requires a prescription.

---

Q: Is there information on the safety of using Ultralan on broken or damaged skin?

Official patient information includes the instruction to avoid applying the product to open sores or areas of broken and infected skin. The medication is strictly prohibited if a patient has an active, untreated infection (such as bacterial or viral) at the intended application site. Use is only permitted if an existing infection is being treated with concurrent anti-infective therapy.

---

Q: Can Ultralan be used at the same time as other topical treatments?

Official patient information provides guidance on using the product alongside other topical treatments, such as moisturizers. If a moisturizer is used, official instructions state that the moisturizer should be applied first. A wait time of 10–15 minutes is then noted in the instructions before applying Ultralan.

---

Q: Is Ultralan known by any other name internationally?

The active ingredient in this medicine is known chemically as Fluocortolone. Official patient information notes that the product was previously marketed under the name Ultralanum Plain®. This trade name, however, has since been discontinued.

Storage and Disposal Requirements

Official instructions define specific storage conditions based on the formulation of Fluocortolone (Ultralan/Ultraproct). All forms must be kept out of the sight and reach of children.

Storage Conditions

Formulation	Required Temperature	Additional Rules
Ointment/Cream	Store below 25 C	Use within 3 months after opening; replace cap tightly.
Suppositories	Store in a refrigerator (2 C to 8 C)	Do not freeze.

Disposal

Expired or unused product must be disposed of properly to protect the environment. Regulatory guidelines prohibit throwing the medicine into household waste or flushing it down wastewater. For the correct procedure, users should consult a pharmacist.